We report here the induction of specific protective cellular immunity against Mycobacterium tuberculosis by the employment of vaccination with recombinant attenuated Listeria monocytogenes strains. We constructed self-destructing attenuated L. monocytogenes ⌬2 strains carrying eukaryotic expression plasmids for the antigen 85 complex (Ag85A and Ag85B) and for MPB/MPT51 (mycobacterial protein secreted by M. bovis BCG/mycobacterial protein secreted by M. tuberculosis) molecules. Infection of these recombinant bacteria allowed expression of the genes in the J774A.1 murine macrophage cell line. Intraperitoneal vaccination of C57BL/6 mice with these recombinant bacteria was capable of inducing purified protein derivative-specific cellular immune responses, such as foot pad reactions, proliferative responses of splenocytes, and gamma interferon production from splenocytes, suggesting the efficacy of vaccination against mycobacterial infection by use of these recombinant L. monocytogenes strains. Furthermore, intravenous vaccination with recombinant bacteria carrying expression plasmids for Ag85A, Ag85B, or MPB/MPT51 in
Tuberculosis (TB) remains an urgent public health problem worldwide, resulting in 8 million new cases and 2 million deaths each year (14) . Outbreaks of TB, especially in immunocompromised people, such as aged groups and AIDS patients, have also been reported. In addition, the appearance of multidrug-resistant Mycobacterium tuberculosis strains is also a serious issue in the world.
The only TB vaccine currently available is the attenuated Mycobacterium bovis strain bacillus Calmette-Guérin (BCG), which has been reported to have a variable protective efficacy, ranging from 0 to 85% in different controlled studies (6) . Therefore, there remains an urgent need for an improved vaccine. A DNA vaccine is one of the most promising candidates for future TB vaccines. Many reports on DNA vaccination against TB have been accumulating. Secreted molecules have been known to be recognized by the protective immune response against TB. In these reports, various target antigens (Ags) for TB DNA vaccination have been reported, including the Ag85 complex molecules, Hsp65, Hsp70, the 38-kDa Ag, and ESAT-6 (reviewed in reference 28).
Ag85 complex molecules have been reported to be the dominant secreted Ags expressed by nearly all mycobacterial species analyzed so far (reviewed in reference 39). The complex consists of three structurally related components, namely Ag85A (p32A; 32-kDa Ag), Ag85B (p30; 30-kDa Ag, also termed ␣ Ag), and Ag85C. Ag85 complex molecules are crossreactive Ags and are highly conserved among Mycobacterium spp. The genes encode proteins with fibronectin-binding capacities (1) and mycolyltransferase activities, which are involved in the final stage of mycobacterial cell wall assembly (5) . Ag85A and Ag85B have been reported to stimulate B-and T-cell responses in TB patients (24, 25) , and immunization with Ag85A and Ag85B proteins induced protection against an aerosol challenge with M. tuberculosis in mice and guinea pigs, respectively (19) . In addition, reports of successful naked DNA vaccines against TB, employing the Ag85A (3, 4, 9, 13, 21, 29, 36, 37) and Ag85B (22, 29, 37) genes, have also accumulated. According to these reports, the Ag85A and Ag85B molecules seem to be two of the most promising candidates for future subunit TB vaccines. Another molecule, MPB/MPT51 (mycobacterial protein secreted by M. bovis BCG/mycobacterial protein secreted by M. tuberculosis), has also been reported to be related to this family (31) . The amino acid sequence deduced for MPB51 (GenBank/EMBL/DDBJ accession number D26486) is identical to the sequence deduced for MPT51 of M. tuberculosis strains H37Rv (AL022076) and CDC1551 (AE007185). So far, MPB/MPT51 has not been reported as a target Ag for vaccination against M. tuberculosis.
DNA vaccines offer many advantages over other methods of immunization: they have a relatively easy design and construction by recombinant DNA techniques, a strong induction of cellular immunity, chemical stability, a relatively low cost, and so on (reviewed in references 2 and 12). For successful results with DNA vaccination (for example, in the case of Ag85A), however, intramuscular immunization with large amounts (50 to 100 g) of plasmid DNA was reported to be necessary (36) , and the induction of immunity with intramuscular immunization of plasmid DNA is poor in terms of reproducibility (41) . Recently, several investigators used attenuated intracellular bacteria as the carriers of DNA vaccines (reviewed in reference 11). These bacterial carrier systems have several special features, including direct delivery of the plasmid DNA to professional antigenpresenting cells and the possibility of oral administration. Bacteria utilized as this type of vaccine carrier include Salmonella (8) and Shigella (35) as well as Listeria (10). Gramnegative carriers such as Salmonella and Shigella have the disadvantage of containing abundant amounts of toxic lipopolysaccharide. Therefore, Listeria monocytogenes, a grampositive bacterium, is a good candidate for a carrier. Furthermore, this bacterium is considered a possible effective recombinant vaccine vector based on its predilection for professional antigen-presenting cells such as macrophages and dendritic cells and its capacity to escape from phagolysosomes and to live in the cytoplasm of host cells (34, 38) . In addition, this bacterium has been reported to have the ability to induce T-helper cell type 1 (Th1) immune responses (20) . These features are favorable for eliciting effective cellular immunity against TB. Dietrich et al. (10) reported a DNA vaccination system using an attenuated self-destructing L. monocytogenes strain. They demonstrated the feasibility of the system in a cell culture system. They used a deletion mutant of L. monocytogenes ⌬2 that lacks the entire lecithinase operon, including the virulence-associated genes actA, mpl, and plcB (17) . This strain can infect macrophages and replicate in the cytoplasm but cannot spread to adjacent cells. This attenuated mutant was introduced with a plasmid containing the gene for lysis protein PLY118 of the listerial bacteriophage A118. PLY118 expression was controlled by the actA promoter, which is active when L. monocytogenes is in the host cell cytoplasm. Thus, this L. monocytogenes mutant escapes from the phagosome and then lyses when the PLY118 gene is expressed in the cytoplasm. Autolysis of the L. monocytogenes mutant apparently releases the plasmid DNA into the host cell cytoplasm, allowing expression of the transgene in the host cells. However, it was still unknown whether this DNA vaccine carrier system is capable of inducing specific immunity and protective immunity against infection in vivo. For this study, we examined the inducibility of protective cellular immunity against M. tuberculosis by immunization of mice with this attenuated L. monocytogenes strain carrying a eukaryotic expression plasmid for Ag85A, Ag85B, or MPB51. The results showed that vaccination with the attenuated selfdestructing L. monocytogenes strain could induce protective cellular immunity against M. tuberculosis infection. Furthermore, we show for the first time that MPB/MPT51, which is related to Ag85 family molecules, is a major protective Ag.
MATERIALS AND METHODS
Bacteria and plasmids. M. bovis BCG (substrain Tokyo) was purchased from Japan BCG Inc. (Tokyo, Japan). The attenuated L. monocytogenes strain ⌬2 (10, 17) and plasmids p3LOVA118 and pcDNA3L (10) were kindly provided by Werner Goebel, Guido Dietrich, and Ivaylo Gentschev (University of Würzburg, Germany). Attenuated L. monocytogenes ⌬2 was cultured in brain heart infusion (BHI) broth (Becton Dickinson, Sparks, Md.) at 37°C. Escherichia coli DH5␣ was cultured in L broth. M. tuberculosis H37Rv was kindly donated by Isamu Sugawara (Research Institute of Tuberculosis, Tokyo, Japan).
Construction of recombinant plasmids p3L118R-Ag85A, p3L118R-Ag85B, and p3L118R-MPB51. The NruI-NotI fragment of p3LOVA118, covering half of the cytomegalovirus (CMV) promoter and the ovalbumin epitope region, was removed and replaced with the corresponding region of pcDNA3L, resulting in p3L118R. This procedure removed the ovalbumin epitope region from p3LOVA118 and recreated a NotI site for future subcloning of genes of interest under control of the CMV promoter. The BCG Ag85A, Ag85B, and MPB51 genes were amplified from plasmids pMB49 (for Ag85A and MPB51) (31) and p␣L-1 (30) (for Ag85B) by PCRs with the following primer pairs: 5Ј-ATAAGA ATGCGGCCGCACCATGCAGCTTGTTGACAGG-3Ј and 5Ј-ATAGTTTAG CGGCCGCTGTTCGGAGCTAGGCGC-3Ј for Ag85A, 5Ј-ATAAGAATGCG GCCGCACCATGACAGACGTGAGCCGA-3Ј and 5Ј-ATAGTTTAGCGGCC GCGGGCCCGTTGATCCCGTCAGCCGGC-3Ј for Ag85B, and 5Ј-ATAAGA ATGCGGCCGCTCGAGCACCATGAAGGGTCGGTCGGCG-3Ј and 5Ј-AT AGTTTAGCGGCCGCGGGCCCGGCACCTGGCTTAGCGGA-3Ј for MPB51 (underlined text indicates a NotI site). These PCR fragments were digested with NotI and inserted into a NotI site of p3L118R. The integrity of the nucleotide sequences was validated by automated DNA sequencing (ABI PRISM 310 genetic analyzer; Applied Biosystems, Foster City, Calif.) using a dye primer cycle sequencing kit (Applied Biosystems). The resultant plasmids were introduced into the attenuated L. monocytogenes ⌬2 strain by electroporation, as described below.
Electroporation of plasmids into L. monocytogenes ⌬2. The electroporation procedure was basically in accordance with a previously described protocol (33) . Briefly, L. monocytogenes ⌬2 cells were shaken in 200 ml of BHI broth at 37°C until an optical density at 600 nm of 1.0. Next, 2,000 U of penicillin G was added and the culture was subjected to a 1-h incubation. The cells were harvested, washed twice with sucrose electroporation buffer (1 mM HEPES [pH 7.0], 0.5 M sucrose), and resuspended in 500 l of the buffer. One hundred microliters of the cell suspension and 1 g of one of the expression plasmids were then transferred to an electroporation cuvette and subjected to electroshock with a Gene-Pulser electroporation apparatus (Bio-Rad Laboratories, Hercules, Calif.). The electroporation conditions were as follows: cuvette gap, 0.4 cm; voltage, 2.5 kV; field strength, 6.25 kV/cm; capacitor, 25 F; and resistor, 200 ⍀. Next, the cell solution was incubated on ice for 10 min, added to 0.7 ml of BHI broth, and incubated at 37°C for 1 h. After centrifugation at 1,200 ϫ g for 15 min at 4°C, 0.6 ml of the solution was removed. The remaining solution was plated onto a Trypticase soy agar plate (Becton Dickinson) containing 12.5 g of tetracycline/ml and was incubated at 37°C for 18 h. Resultant tetracycline-resistant colonies were cultured and stored. These were named ⌬2/p3L118R, ⌬2/p3L118R-Ag85A, ⌬2/ p3L118R-Ag85B, and ⌬2/p3L118R-MPB51 and harbored the recombinant plasmids p3L118R, p3L118R-Ag85A, p3L118R-Ag85B, and p3L118R-MPB51, respectively.
Mammalian cell culture. The murine macrophage-like cell line J774A.1 (American Type Culture Collection, Manassas, Va.) and spleen cells of immunized mice were cultured in RPMI 1640 medium supplemented with 10% heatinactivated fetal bovine serum in a humidified atmosphere of 5% CO 2 in an incubator.
Infection of J774A.1 cells with recombinant L. monocytogenes ⌬2 strains. J774A.1 cells (5 ϫ 10 5 cells) were plated on 60-mm-diameter plates at the beginning of experiments. The medium was renewed 24 h before the experiments. Recombinant ⌬2 strains (10 5 cells) were added to J774A.1 cells. After 5 h, 10 g of gentamicin sulfate/ml was added to the medium to remove extracellular bacteria. After a 36-h incubation, the infected cells were harvested.
Reverse transcription (RT)-PCR analysis for Ag85A, Ag85B, or MPB51 gene detection. ⌬2/p3L118R-, ⌬2/p3L118R-Ag85A-, ⌬2/p3L118R-Ag85B-, or ⌬2/ p3L118R-MPB51-infected J774A.1 cells were harvested, and total RNAs were prepared from the cells by use of Isogen RNA extraction solution (Nippon Gene, Tokyo, Japan). Single-stranded cDNAs were synthesized with Molony murine leukemia virus reverse transcriptase (Life Technologies, Gaithersburg, Md.) and then were used for PCR analysis. The primers used for Ag85A, Ag85B, and MPB51 gene detection were as follows: for Ag85A, 5Ј-AGGCCAACAGGCAC GTCAA-3Ј and 5Ј-ACATGTCGGAGGCCTTGTA-3Ј; for Ag85B, 5Ј-GAACA ACTCACCTGCGGTT-3Ј and 5Ј-CATCGACAAGCCGATTGC-3Ј; and for MPB51, 5Ј-GATGTCAGTAACTGGGTCAC-3Ј and 5Ј-ACATTCCGTTGGTG TCCACA-3Ј. To refute the possibility of contamination of the plasmids in cDNA pools, we performed PCRs with combinations of a primer located in the CMV enhancer-promoter region of p3L118R, 5Ј-GGTGGGAGGTCTATATAAGC-3Ј, and the reverse primers for the Ag85A, Ag85B, and MPB51 genes.
Mice. C57BL/6 and BALB/c mice (Japan SLC, Hamamatsu, Japan) were kept under specific-pathogen-free conditions and fed autoclaved food and water ad libitum at the Experimental Animal Institute of the Hamamatsu University School of Medicine. All animal experiments were performed according to the Guidelines for Animal Experimentation, Hamamatsu University School of Medicine.
Immunization procedures. Mice were immunized intraperitoneally (i.p.) (C57BL/6; ϳ10 7 CFU) or intravenously (i.v.) (BALB/c; ϳ10 6 CFU) with a recombinant attenuated L. monocytogenes ⌬2 strain three times at 2-week intervals. As a control, mice were also immunized with BCG i.p. once (C57BL/6, ϳ10 7 CFU) or subcutaneously twice at a 2-week interval (BALB/c, ϳ10
6 CFU). Genomic DNA PCR. ⌬2/p3L118R-MPB51 or ⌬2/p3L118R Listeria (ϳ10 8 CFU) was injected i.p. into C57BL/6 mice, and ⌬2/p3L118R-MPB51 or L. monocytogenes EGD (a parental strain of ⌬2; ϳ10 7 CFU) was injected i.v. into BALB/c mice. One day after the injection, tissue cell suspensions from injected mice were prepared and washed three times after the lysis of erythrocytes with Tris-buffered 0.83% ammonium chloride solution. After a brief centrifugation, the cells were added to 10 volumes of proteinase K solution (1 mg/ml; Boehringer Mannheim GmbH, Mannheim, Germany) in 10 mM Tris (pH 7.4), 10 mM EDTA, 150 mM NaCl, and 0.4% sodium dodecyl sulfate and were incubated for 15 min at 65°C. The cells were further incubated in the same solution overnight at 37°C. Genomic DNA was prepared from the cells after phenol extraction and ethanol precipitation. A nested PCR was performed with 1 g of genomic DNA for MPB51 gene detection. The first-round PCR was performed with the same primer pairs that were used for RT-PCR analysis, and the second-round PCR was performed with 1 l of the first-round PCR solution (20-l total volume) and the following primer pairs located just inside of the first-round PCR primers: 5Ј-CGCGGGTAACGCGATGAACAC-3Ј and 5Ј-CACACCGCCGAATTGCT GCAT-3Ј. For both PCRs, the conditions were 25 cycles of 94°C for 30 s, 62°C for 50 s, and 72°C for 30 s. The expected size of the MPB51 PCR product was 341 bp.
Delayed-type hypersensitivity (DTH) reaction. Purified protein derivative (PPD) was purchased from Japan BCG Inc. C57BL/6 mice were injected with 5 g of PPD in 50 l of phosphate-buffered saline (PBS) in the left hind foot pad. As controls, mice were injected with 50 l of PBS alone in the right hind foot pad. The swelling of foot pads was measured with a caliper meter (Mitsutoyo Corp., Osaka, Japan) 48 h after injection. Naïve mice were treated in the same way as the controls for nonspecific swelling.
Lymphocyte proliferation assay. Spleen cells (10 5 /well) from the immunized C57BL/6 mice were incubated for 48 h at 37°C in 96-well round-bottom tissue culture plates in the presence or absence of 5 g of PPD/ml. After 48 h of culturing, de novo DNA synthesis was assessed by the addition of 0. cells/well in RPMI-10% fetal bovine serum in the presence or absence of 5 g of PPD solution/ml. Concentrations of gamma interferon (IFN-␥), interleukin-4 (IL-4), and IL-5 in the culture supernatants were determined by a sandwich enzyme-linked immunosorbent assay (ELISA) as described elsewhere (40) . For the sandwich ELISA, the following combinations of coating and biotinylated monoclonal antibodies were used: R4-6A2 and XMG1.2 for IFN-␥, 11B11 and BVD6-24G2 for IL-4, and TRFK5 and TRFK4 for IL-5. All monoclonal antibodies were purchased from BD PharMingen (San Diego, Calif.). The amounts of cytokines were calculated by using standard murine recombinant cytokine curves run on the same immunoplate.
Semiquantitative RT-PCR for IFN-␥ gene. Immune spleen cells (C57BL/6 mice) were cultured for 48 h at 10 7 cells/ml in the presence or absence of 5 g of PPD solution/ml. Total RNAs were extracted from cells by use of Isogen RNA extraction solution (Nippon Gene). Single-stranded cDNAs were synthesized with Molony murine leukemia virus reverse transcriptase (Life Technologies) and then used in PCRs for IFN-␥ gene detection as described elsewhere (40) .
In vivo protection assay. Immunized BALB/c mice were infected with 5 ϫ , and MPB51 mRNAs in murine macrophage cells infected with ⌬2/p3L118R-Ag85A, ⌬2/ p3L118R-Ag85B, or ⌬2/p3L118R-MPB51. (A) Murine macrophage cell line J774A.1 was infected with ⌬2/p3L118R, ⌬2/p3L118R-Ag85A, ⌬2/p3L118R-Ag85B, or ⌬2/p3L118R-MPB51. Total RNAs from these infected cells were recovered and reverse transcribed with random hexamers to make cDNA pools. PCRs were then performed with Ag85A, Ag85B, and MPB51 gene-specific primers (cDNA panels). After the recovery of total RNAs, the same PCRs were performed for Ag85A, Ag85B, or MPB51 gene detection without RT (RNA panels). (B) To refute the possibility of contamination of p3L118R-Ag85A, p3L118R-Ag85B, or p3L118R-MPB51 in the cDNA pools used for panel A, we subjected the cDNA pools to PCRs with primer sets by which only the plasmid DNAs, not the transcripts, were detected. See Materials and Methods for details. 
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Ag85A, p3L118R-Ag85B, or p3L118R-MPB51. Thirty-six hours after infection, the infected cells were harvested for the isolation of total RNA. RT-PCR was then performed to confirm the expression of Ag85A, Ag85B, or MPB51 mRNA in the cells. As shown in Fig. 1A , clear bands for these mRNAs were detected after RT of total RNA solutions but not before reverse transcriptase treatment. In addition, to refute the possibility of contamination of plasmids p3L118R-Ag85A, p3L118R-Ag85B, and p3L118R-MPB51 in the cDNA pools used, we subjected the cDNA pools to PCRs with relevant primer sets, by which only the plasmid DNAs, but not the transcripts, were detected (see Materials and Methods for details). The results showed that no bands were detected with the cDNA pools by PCR, while p3L118R-Ag85A, p3L118R-Ag85B, and p3L118R-MPB51 controls gave specific bands, indicating no contamination of plasmids in the cDNA pools. These data indicate that the Ag85A, Ag85B, and MPB51 genes were expressed in J774A.1 cells by this attenuated L. monocytogenes system. Detection of injected plasmid DNA in tissues of mice infected with recombinant attenuated L. monocytogenes. ⌬2/ p3L118R-MPB51 recombinant Listeria was injected i.p. (C57BL/6 mice) or i.v. (BALB/c mice). In order to check for p3L118R-MPB51 plasmid transfer to tissues of the injected mice, we prepared genomic DNAs from cells of the tissues and performed PCR analysis for MPB51 gene detection. As shown in Fig. 2 , we observed an MPB51-specific band only for DNAs derived from mice injected with ⌬2/p3L118R-MPB51 Listeria. The PCR was performed with tissue cells washed with PBS, suggesting that the p3L118R-MPB51 plasmid was transferred into host cells after recombinant Listeria injection. It is noteworthy that we observed no colonies of carrier L. monocytogenes in the spleens of the i.p. immunized C57BL/6 mice by plating of the tissue homogenates on Trypticase soy agar (data not shown).
PPD-specific DTH reaction with recombinant attenuated L. monocytogenes vaccination. For effective protective immunity against M. tuberculosis, specific cellular immunity against the bacterium plays a critical role. We first examined DTH responses of C57BL/6 mice immunized with ⌬2/p3L118R-Ag85A, ⌬2/p3L118R-Ag85B, or ⌬2/p3L118R-MPB51. As shown in Fig. 3 , mice immunized with these recombinant Listeria strains significantly responded to PPD, but not to PBS alone. Similar, but lower, responses were obtained for mice immunized with M. bovis BCG. Mice immunized with the ⌬2/ p3L118R control strain failed to show specific DTH reactions to PPD. These results indicate that mice immunized with ⌬2/ p3L118R-Ag85A, ⌬2/p3L118R-Ag85B, or ⌬2/p3L118R-MPB51 successfully elicited cellular immunity against M. tuberculosis.
PPD-specific lymphocyte proliferation after recombinant attenuated L. monocytogenes vaccination. We next examined proliferative responses of splenocytes derived from the immunized C57BL/6 mice in response to in vitro PPD stimulation. As shown in Fig. 4 , a strong proliferative response was observed in control BCG-immunized mice. Immunization with recombinant ⌬2/p3L118R-Ag85A, ⌬2/p3L118R-Ag85B, or ⌬2/ p3L118R-MPB51 also caused significant proliferative responses, but the levels of specific proliferation were lower than that evoked by immunization with M. bovis BCG. Splenocytes of mice immunized with the ⌬2/p3L118R control recombinant L. monocytogenes strain did not have a significant response. PPD-specific cytokine production with recombinant attenuated L. monocytogenes vaccination. IFN-␥ is known to be a key factor for the elicitation of effective protection against M. tuberculosis. Therefore, employing RT-PCR analysis, we semiquantitatively assessed IFN-␥ mRNA expression from splenocytes of immunized C57BL/6 mice upon PPD stimulation. As shown in Fig. 5 , IFN-␥ mRNA-specific bands were clearly detected in PPD-stimulated splenocytes of C57BL/6 mice immunized with recombinant Listeria strain ⌬2/p3L118R-Ag85A, ⌬2/p3L118R-Ag85B, or ⌬2/p3L118R-MPB51. The strengths of the bands were comparable to that of mice immunized with M. bovis BCG. Again, splenocytes of mice immunized with the ⌬2/p3L118R control gave only a faint IFN-␥ mRNA-specific band.
In addition, we examined the cytokine production of splenocytes from immunized C57BL/6 mice by a sandwich ELISA for IFN-␥, IL-4, and IL-5 (Table 1) . Correlating with the results of RT-PCRs, splenocytes from mice immunized with M. bovis BCG or a recombinant Listeria strain harboring the Ag85A, Ag85B, or MPB51 gene produced high amounts of IFN-␥ after in vitro stimulation with PPD. We observed the production of moderate levels of IFN-␥ from spleen cells of naïve mice and control Listeria (⌬2/p3L118R)-immunized mice upon PPD stimulation. We did not detect significantly enhanced production of IL-4 or IL-5 for any of the mice examined.
Recombinant attenuated L. monocytogenes vaccination conferred protective immunity against M. tuberculosis infection comparable to M. bovis BCG immunization in BALB/c mice.
FIG. 4. PPD-specific splenocyte proliferation of mice immunized
with ⌬2/p3L118R-Ag85A, ⌬2/p3L118R-Ag85B, or ⌬2/p3L118R-MPB51. C57BL/6 mice were immunized with ⌬2/p3L118R, ⌬2/ p3L118R-Ag85A, ⌬2/p3L118R-Ag85B, or ⌬2/p3L118R-MPB51 three times at 2-week intervals. The data for mice immunized once with M. bovis BCG are also shown as a control. Spleen cells from the immunized mice were harvested 1 month after the last immunization, cultured in vitro in the presence or absence of 5 g of PPD/ml for 48 h, and pulsed with 0. We evaluated the effects of recombinant attenuated Listeria vaccination on protective immunity against M. tuberculosis H37Rv infection and compared them with those of M. bovis BCG vaccination. At first, we used C57BL/6 mice for the experiments, but the relative resistance against M. tuberculosis infection of the strain hampered the evaluation of the vaccination effects. Therefore, we used BALB/c mice for the evaluation. Ten weeks after i.v. injection with M. tuberculosis H37Rv, spleens, livers, and lungs were prepared from the immunized mice and the numbers of CFU of M. tuberculosis H37Rv in these tissues were evaluated. Figure 6 shows viable colony counts for tissues from mice immunized with ⌬2/ p3L118R-Ag85A, ⌬2/p3L118R-Ag85B, or ⌬2/p3L118R-MPB51 Listeria compared with those from naïve mice, mice immunized with the ⌬2/p3L118R control, and BCG-vaccinated mice. The protective effects of these recombinant Listeria immunizations were obvious in all tissues examined and were comparable to those of live BCG vaccination. In the liver, particularly, we detected an approximately 2-orders-of-magnitude reduction in CFU for Ag85A, Ag85B, and MPB51 DNA vaccine-and live BCG-immunized mice. The MPB/MPT51 molecule, which is related to the Ag85 family, appears to be a major protective Ag, in addition to Ag85A and Ag85B.
We detected a significant level of PPD-specific IFN-␥ secretion, which is a hallmark of type 1 immune responses and is considered an important factor in the protective immunity against M. tuberculosis (7, 15, 23) , in splenocytes of mice immunized with attenuated recombinant Listeria harboring an Ag85A, Ag85B, or MPB/MPT51 DNA vaccine ( Table 1 ). The production of moderate levels of IFN-␥ from splenocytes of naïve mice and control Listeria (⌬2/p3L118R)-immunized mice may be caused by nonspecific responses of these mice against PPD.
Cellular immunity, including CD8 ϩ cytotoxic T lymphocytes and CD4
ϩ Th1 cells, has been reported to play critical roles in effective protective immunity against M. tuberculosis (reviewed in references 16 and 32) . In this context, the attenuated Listeria immunization system shown here should be a favorable immunization method, as it is able to elicit effective type 1 cellular immune responses against M. tuberculosis. Furthermore, an attenuated Listeria strain harboring the suicide gene ply118 was revealed to be almost nontoxic, since inoculation with ϳ10 8 CFU of the attenuated Listeria, but not virulent L. monocytogenes, failed to kill even IFN-␥ receptor knockout mice as well as C57BL/6 wild-type mice (data not shown). Also, we could not detect carrier L. monocytogenes, although the plasmid DNA vaccines were detected in the spleens of i.p. immunized C57BL/6 mice (data not shown).
Several heterologous carrier systems for mycobacterial Ags have been reported. Zhu et al. (42) showed that the recombinant vaccinia virus system for M. tuberculosis-derived 19-and 38-kDa glycolipoproteins is effective for protection against murine M. tuberculosis infection. Hess et al. (18) reported that a recombinant Salmonella enterica serovar Typhimurium vaccine which secretes Ag85B is effective for the induction of pathogen-specific IFN-␥ and tumor necrosis factor and also for protection against murine TB. It will be interesting to compare the system shown here with these systems in terms of the induction of protective immunity against M. tuberculosis.
As a general rule, the determination of a target Ag is very important for the development of effective DNA vaccines FIG. 6 . In vivo protective activity of mice immunized with ⌬2/p3L118R-Ag85A, ⌬2/p3L118R-Ag85B, or ⌬2/p3L118R-MPB51 against virulent M. tuberculosis. BALB/c mice were immunized with ⌬2/p3L118R, ⌬2/p3L118R-Ag85A, ⌬2/p3L118R-Ag85B, or ⌬2/p3L118R-MPB51 three times at 2-week intervals. The data for mice immunized once with M. bovis BCG are also shown as a control. The mice were challenged i.v. with live M. tuberculosis H37Rv. Numbers of CFU in the spleens, livers, and lungs were determined 10 weeks later. The means Ϯ SD of six mice are shown. Asterisks indicate statistically significant (P Ͻ 0.05) differences with the value for a control (⌬2/p3L118R) immunization.
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LISTERIA-BASED DNA VACCINES AGAINST M. TUBERCULOSIS 2019 against bacterial infection. Many reports have already shown the effectiveness of Ag85A and Ag85B for eliciting protective immunity against M. tuberculosis. We also confirmed with our system that Ag85A and Ag85B are capable of inducing cellular and protective immunity. In addition, we evaluated the effectiveness of MPB/MPT51 as a target Ag for an anti-TB vaccine.
Our results indicate that MPB/MPT51 is also a protective Ag and is comparable to Ag85A and Ag85B. In particular, immunization with ⌬2/p3L118R-MPB51 induced enhanced PPDspecific IFN-␥ production from splenocytes, the expression level of which was comparable to that by BCG immunization. So far, MPB/MPT51 has not been reported as a target Ag for vaccination. Therefore, it is interesting and important to examine the antigenicity of the molecule in detail to study, for example, the capacity to induce specific CD4 ϩ -and CD8 ϩ -Tcell effectors, and to identify the T-cell epitopes in the molecule. We identified T-cell epitopes in C57BL/6 and BALB/c mice (M. Suzuki, T. Aoshi, T. Nagata, and Y. Koide, submitted for publication). The spleen cells derived from ⌬2/p3L118R-MPB51-immunized mice were able to induce IFN-␥ in response to these epitope peptides, indicating that the responses are MPB51 specific (data not shown).
For the induction of effective immunity, the route of vaccination is an important factor. The Listeria carrier system is suitable for the induction of mucosal immunity. Particularly, intranasal inoculation of our recombinant Listeria strains may be capable of inducing protective T-cell immune responses in the lung. That study is now in progress. For the present study, however, we immunized mice with Listeria i.p. (C57BL/6 mice) or i.v. (BALB/c mice). The main reason for not choosing the oral route for immunization is that the mouse was reported not to be a good model for the entry of L. monocytogenes into intestinal epithelium due to a Glu-to-Pro substitution in mouse E-cadherin, which serves as a receptor for internalin A of L. monocytogenes (26, 27) . In humans, however, oral immunization with L. monocytogenes-harboring plasmid DNA vaccines seems to be a possible choice for DNA vaccine delivery. Although mice are devoid of the E-cadherin molecule, L. monocytogenes may have a capacity to enter into M cells located in the intestinal epithelium. Therefore, oral administration of attenuated L. monocytogenes strains is also worthwhile to try in mice.
Taken together, we show here that DNA vaccines with the attenuated self-destructing L. monocytogenes carrier system may be favorable DNA vaccination systems in vivo when accompanied with the adjuvanticity to induce Th1-type immune responses and the predilection of the bacterium to interact with macrophages.
